Evidence map›Paper›PMID 37786617›Full record

ArticleCurrent health sciences journal

Investigating the Neuroprotective and Neuroregenerative Effect of Trazodone Regarding Behavioral Recovery in a BL6C57 Mice Stroke Model.

Ianis Kevyn Stefan Boboc, Alina Catalina Chirea, Victor Gheorman, Andrei Gresita, Tudor-Adrian Balseanu, Bogdan Catalin, Daniela Calina

Open access · greenAbstract read
In one paragraph

Article in Current health sciences journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Ianis Kevyn Stefan BobocU.M.F. Doctoral School Craiova, University of Medicine and Pharmacy of Craiova, Romania.
Alina Catalina ChireaExperimental Research Centre for Normal and Pathological Aging, University of Medicine and Pharmacy of Craiova, Romania.
Victor GheormanDepartment of Psychiatry, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Romania.
Andrei GresitaCollege of Osteopathic Medicine, New York Institute of Technology, Old Westbury, NY 11568, USA.
Tudor-Adrian BalseanuExperimental Research Centre for Normal and Pathological Aging, University of Medicine and Pharmacy of Craiova, Romania.
Bogdan CatalinExperimental Research Centre for Normal and Pathological Aging, University of Medicine and Pharmacy of Craiova, Romania.
Daniela CalinaDepartment of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, Romania.
University of Medicine and Pharmacy of Craiova · RONew York Institute of Technology · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stroke is a major cause of death and disability worldwide. Between 1990 and 2010, its global burden increased notably with reference to the absolute number of incident events, number of deaths, and disability-adjusted life-years lost. Trazodone is a triazolopyridine derivative that was approved for more than 40 years as monotherapy or in combination with other antidepressant drugs for the treatment of major depressive disorder in adult patients. The aim was investigated if trazodone can improve behavioural outcome after stroke in a mice model of middle cerebral artery occlusion (MCAo) due to the potential neuroprotective and neurodegenerative effects by using three behavioural tests: adhesive tape test, beam test and hole board test. Trazodone administration show modest improvements regarding the motor-sensorial function after stroke especially in the acute post-stroke phase in aged and young animals. The antidepressant effect of the drug was observed in the post-stroke period in aged animals and to a lesser extent in young animals. Future research is needed to evaluate the effects of trazodone at the cellular level to be sure that it has no benefit in stroke patients who do not suffer from depression.

Indexed as

behavioral testdrug repurposingStroketrazodone

Identifiers

PMID37786617
PMCPMC10541511
OpenAlexW4387296432

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.